Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Thousands to benefit as weight loss drug Mounjaro approved for new use - Australia and the United States have both approved ...

As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

Three dads share how their bodies and family relationships have changed since they began taking GLP-1 weight loss medications ...

Communities across Asia's Himalayan Hindu Kush region face heightened disaster risks this monsoon season with temperatures ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Researchers are studying axolotls -- "small, smiling salamanders" -- in the hopes of learning how humans might one day regrow ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

McDonald's faces a potential decline in sales due to the weight loss medications. Other fast-food chains like Domino's and KFC are also at risk, while Taco Bell and Chipotle are better positioned.

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.